JP2020522549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522549A5 JP2020522549A5 JP2019567641A JP2019567641A JP2020522549A5 JP 2020522549 A5 JP2020522549 A5 JP 2020522549A5 JP 2019567641 A JP2019567641 A JP 2019567641A JP 2019567641 A JP2019567641 A JP 2019567641A JP 2020522549 A5 JP2020522549 A5 JP 2020522549A5
- Authority
- JP
- Japan
- Prior art keywords
- apo
- rtx
- cells
- survival
- synergistic effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 9
- 229960004641 rituximab Drugs 0.000 description 9
- 230000002195 synergetic effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762516714P | 2017-06-08 | 2017-06-08 | |
| US62/516,714 | 2017-06-08 | ||
| US201762549465P | 2017-08-24 | 2017-08-24 | |
| US62/549,465 | 2017-08-24 | ||
| PCT/IL2018/050621 WO2018225072A1 (en) | 2017-06-08 | 2018-06-07 | Therapeutic apoptotic cells for cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522549A JP2020522549A (ja) | 2020-07-30 |
| JP2020522549A5 true JP2020522549A5 (cg-RX-API-DMAC7.html) | 2021-08-26 |
| JP7321101B2 JP7321101B2 (ja) | 2023-08-04 |
Family
ID=64566093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567641A Active JP7321101B2 (ja) | 2017-06-08 | 2018-06-07 | 癌治療のための治療的アポトーシス細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11951126B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3612192A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7321101B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200014418A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110996972A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018282127B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3064893A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL270697A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018225072A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| IL297418B2 (en) | 2015-02-18 | 2023-11-01 | Enlivex Therapeutics Rdo Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| AU2016250570B2 (en) | 2015-04-21 | 2021-07-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
| EP4232078A4 (en) * | 2020-10-20 | 2025-01-22 | The Regents of The University of California | ATTENUATED CANCER CELLS AND RELATED METHODS |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6489311B1 (en) | 2000-05-02 | 2002-12-03 | Charlotte-Mecklenburg Hospital Authoirty | Method for the prevention of apoptosis |
| US9944713B2 (en) * | 2004-11-24 | 2018-04-17 | Medicinal Bioconvergence Research Center | Antibody specific to the AIMP2-DX2 |
| ES2686424T5 (es) | 2010-05-04 | 2023-03-27 | Yeda Res & Dev | Inmunoterapia con células alogénicas redireccionadas |
| EA201590210A1 (ru) * | 2012-07-13 | 2015-08-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов |
| US20140127179A1 (en) * | 2012-11-02 | 2014-05-08 | Scientific Formulations, Llc | Natural Killer Cell Formulations |
| CN105102612B (zh) * | 2012-12-06 | 2020-11-17 | 恩立夫克治疗有限责任公司 | 治疗性凋亡细胞制剂、其制备方法以及其用途 |
| SG11201700774UA (en) * | 2014-08-01 | 2017-02-27 | Pharmacyclics Llc | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
| US11497767B2 (en) * | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) * | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| IL297418B2 (en) * | 2015-02-18 | 2023-11-01 | Enlivex Therapeutics Rdo Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) * | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) * | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11000548B2 (en) * | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| AU2016250570B2 (en) * | 2015-04-21 | 2021-07-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| JP6884155B2 (ja) * | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
-
2018
- 2018-06-07 JP JP2019567641A patent/JP7321101B2/ja active Active
- 2018-06-07 AU AU2018282127A patent/AU2018282127B2/en not_active Expired - Fee Related
- 2018-06-07 WO PCT/IL2018/050621 patent/WO2018225072A1/en not_active Ceased
- 2018-06-07 KR KR1020207000485A patent/KR20200014418A/ko not_active Ceased
- 2018-06-07 EP EP18812666.8A patent/EP3612192A4/en not_active Withdrawn
- 2018-06-07 CN CN201880051674.0A patent/CN110996972A/zh active Pending
- 2018-06-07 CA CA3064893A patent/CA3064893A1/en active Pending
-
2019
- 2019-09-19 US US16/576,734 patent/US11951126B2/en active Active
- 2019-11-17 IL IL270697A patent/IL270697A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522549A5 (cg-RX-API-DMAC7.html) | ||
| JP2019503365A5 (cg-RX-API-DMAC7.html) | ||
| Zatloukal et al. | Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial | |
| JP2019534308A5 (cg-RX-API-DMAC7.html) | ||
| JP2013147511A5 (cg-RX-API-DMAC7.html) | ||
| Schiller et al. | Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer | |
| KR20140019364A (ko) | 면역-관련 및 염증성 질환의 치료에 있어서의 3-(5-아미노-2-메틸-4-옥소퀴나졸린-3(4ｈ)-일)피페리딘-2-6-디온의 용도 | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| NZ627837A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| CN109985237B (zh) | 一种治疗结直肠癌的药物组合物及其应用 | |
| RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| JP2017537927A5 (cg-RX-API-DMAC7.html) | ||
| JP2016505050A5 (cg-RX-API-DMAC7.html) | ||
| Kozlov et al. | Nivolumab in pediatric Hodgkin's lymphoma | |
| Ulbricht et al. | An evidence-based systematic review of active hexose correlated compound (AHCC) by the Natural Standard Research Collaboration | |
| Introcaso et al. | Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome | |
| JP2006508994A5 (cg-RX-API-DMAC7.html) | ||
| CN1711090A (zh) | 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合 | |
| JP2022511126A (ja) | Ｒ－ｃｈｏｐとの組み合わせ及び複合薬におけるチダミドの適用 | |
| JP2016525530A (ja) | 急性骨髄性白血病及び骨髄異形成症候群の処置のためのボラセルチブと組み合わせたデシタビン | |
| JP6708634B2 (ja) | 急性骨髄性白血病及び骨髄異形成症候群の併用療法ｉｉｉ | |
| TWI375671B (en) | Pharmaceutical compositions containing brazilin for inhibiting expression of cytokines of t helper cell type ii and/or inhibiting expression of chemokines and uses of the same | |
| CN111228264A (zh) | 西达本胺联合cgb以及自体造血干细胞的应用及联合药物 | |
| Lu et al. | Use of combination therapies including the XPO1 inhibitor selinexor in is a potential effective therapeutic strategy to treat myelofibrosis patients | |
| JP2015520763A5 (cg-RX-API-DMAC7.html) |